How much funding has Xilis raised?

Xilis has raised $92.0M in total funding, most recently a Series A round.

Who are Xilis's investors?

Xilis's investors include Felicis Ventures, Fpv Ventures, Mubadala Capital, Pear VC, Alexandria Venture Investments, EQT AB.

Where is Xilis headquartered?

Xilis is headquartered in Durham, North Carolina, United States.

What industry is Xilis in?

Xilis operates in Biotech, Diagnostics, Drug Discovery, Life Sciences.

Xilis

Revolutionizing Drug Discovery and Development with Patient-Derived MicroOrganoSpheres®

Durham, United States · Founded 2019 · $92.0M raised

Headquarters: Durham, North Carolina
Employees: 51–200
Founded: 2019
Business Model: B2B

Website: xilis.com
Total Funding: $92.0M
Last Round: $19.0M Series AApr 2025
Rounds: 3

About

Xilis develops advanced patient-derived organoid technology to accelerate pharmaceutical development and improve cancer treatment outcomes. The company's proprietary MicroOrganoSphere® (MOS) platform creates 3D micro-tumor models that preserve the cellular composition, genetic alterations, immune microenvironment, and histopathology of primary patient tissue. These models enable more accurate drug efficacy predictions and reduce risk throughout the drug discovery and development lifecycle—from initial discovery through clinical trials—spanning immuno-oncology, chemotherapy, and cell therapy applications. The platform integrates automated model creation, customizable assays, and AI-powered analytics to support both precision oncology diagnostics and pharmaceutical R&D partnerships.

Summary

Xilis is a Biotech company based in Durham, United States, founded in 2019. It has raised $92.0M in total across 3 rounds, most recently a $19.0M Series A round in Apr 2025. Investors include Felicis Ventures, Fpv Ventures and Mubadala Capital.